SCHEMBL1669609

SCHEMBL1669609

CCOc1nc(-c2nc(Cc3ccc(F)cc3)no2)c(OCc2ccccc2)c(=O)n1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.42
CYP1A2 P05177 4/20 0.42
CASP1 P29466 2/20 0.42
CASP7 P55210 2/20 0.42
HSD17B10 Q99714 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
MAPK1 P28482 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
CHUK O15111 1/20 0.38
TXNRD1 Q16881 1/20 0.38
NOX4 Q9NPH5 1/20 0.38
PKM P14618 1/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
CYP3A4 P08684 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12225688 0.87 ADORA2B (0.37) ALDH1A1MAPK1L3MBTL1APLNR
SCHEMBL1672331 0.84 APLNR (0.39) ALDH1A1MAPK1SMN1; SMN2NPC1RAB9A
SCHEMBL1669215 0.84 MCHR1 (0.42) ALDH1A1CYP1A2CASP1CASP7HSD17B10
SCHEMBL1669189 0.83 ALDH1A1 (0.40) ALDH1A1CYP1A2CASP1CASP7HSD17B10
SCHEMBL12225746 0.72 PLAT (0.39) KMT2AL3MBTL1NMT1APLNR
SCHEMBL12225285 0.71 ALDH1A1 (0.36) ALDH1A1CYP1A2CASP1CASP7HSD17B10
SCHEMBL2507511 0.69 MAOA (0.48) ALDH1A1CYP1A2CASP1CASP7HSD17B10
SCHEMBL13218123 0.69 CYP1A2 (0.42) ALDH1A1CYP1A2CASP1CASP7HSD17B10
SCHEMBL2545473 0.66 SMN1; SMN2 (0.42) ALDH1A1CYP1A2CASP1CASP7HSD17B10
SCHEMBL13293149 0.65 CYP1A2 (0.40) ALDH1A1CYP1A2CASP1CASP7HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383639-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-02-26 US disclosed
US-8383639-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-02-26 US disclosed
EP-2488517-A1 HIV INTEGRASE INHIBITORS Bristol-Myers Squibb Company (US) 2012-08-22 EP disclosed
US-20110245241-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2011-10-06 US disclosed
US-20110245241-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2011-10-06 US disclosed
WO-2011046873-A1 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245241-A1 HIV Integrase Inhibitors DNTT, POLB, UNG ALDH1A1 539/4885CYP1A2 681/4885CASP1 2481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.